> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-90/
- Published: 2017-01-16T12:00:00.000Z
- Updated: 2026-09-14T22:00:17.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137734

**Forward Pharma A/S** has entered into a binding agreement with two wholly owned subsidiaries of **Biogen** and certain other parties. Under the agreement, Biogen will pay Forward $1.25 billion and it will be obligated to pay Forward royalties of up to 10-20% of net sales of Biogen products, including Tecfidera, approved for treating multiple sclerosis that are covered by a Forward patent and have dimethyl fumarate as an active pharmaceutical ingredient.

**Novan** has entered into an exclusive license agreement with **Sato Pharmaceutical Co.**, a Japanese company with a prescription pharmaceutical business specializing in dermatology. Under the agreement, Sato will pay Novan an initial payment of $11.0 million for the exclusive rights to develop and commercialize in Japan Novan’s topical nitric oxide-releasing product candidate SB204 and related dosage forms for the treatment of acne vulgaris.

**Intas Pharmaceuticals Ltd.**, through its wholly owned subsidiary **Accord Healthcare Ltd.**, has acquired **Actavis UK Ltd.** and **Actavis Ireland Ltd.** from **Teva Pharmaceutical Industries Ltd.** for £603 million. The transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of **Allergan**’s generics business.

**Hill-Rom** has signed a definitive agreement to acquire **Mortara Instrument Inc.** for $330 million. Integration of Mortara’s portfolio is expected to expand and enhance Hill-Rom’s offerings in the diagnostic cardiology and vital sign monitoring markets, as well as accelerate growth for Mortara technology on a global scale.